Multiple vaccination including serogroup C meningococcus
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorAstrid Borkowski
Life of this patent
Estimating the term…
Abstract
Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.
Claims37
A kit, comprising a first immunogenic component, a second immunogenic component and a third immunogenic component, wherein:
- (a) the first immunogenic component comprises an aqueous formulation of conjugated capsular saccharides from Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F and an aluminium phosphate adjuvant;
- (b) the second immunogenic component comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C;
- (c) at least one of the Streptococcus pneumoniae conjugates has the same carrier protein as the Neisseria meningitidis serogroup C conjugate, wherein said carrier protein is a bacterial toxin in toxoid form;
- and (d) the third immunogenic component comprises one or more of:
- a diphtheria toxoid, a tetanus toxoid, a B. pertussis antigen, a hepatitis B virus surface antigen, a conjugated Haemophilus influenzae type B antigen, and an inactivated poliovirus antigen, where, if one of these six additional antigens is included in the first or second immunogenic component, it will not be included in the third immunogenic component.
A kit, comprising a first immunogenic component and a second immunogenic component, wherein:
- (a) one of the immunogenic components comprises conjugated capsular saccharides from Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F and an aluminium phosphate adjuvant;
- (b) one of the immunogenic components comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C;
- (c) one of the immunogenic components comprises an inactivated poliovirus antigen;
- and (d) at least one of the Streptococcus pneumoniae conjugates has the same carrier protein as the Neisseria meningitidis serogroup C conjugate, wherein said carrier protein is a bacterial toxin in toxoid form.
An immunogenic composition comprising (i) conjugated capsular saccharides from Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F and an aluminium phosphate adjuvant;
- (ii) conjugated capsular saccharide from Neisseria meningitidis serogroup C;
- and (iii) an inactivated poliovirus antigen, wherein (a) the composition is in aqueous form and (b) at least one of the Streptococcus pneumoniae conjugates has the same carrier protein as the Neisseria meningitidis serogroup C conjugate, wherein said carrier protein is a bacterial toxin in toxoid form.
Dependencies are inferred from the claim text.